TY - JOUR
T1 - Urokinase receptor forms in serum from non-small cell lung cancer patients
T2 - relation to prognosis
AU - Almasi, Charlotte Elberling
AU - Christensen, Ib Jarle
AU - Høyer-Hansen, Gunilla
AU - Danø, Keld
AU - Pappot, Helle
AU - Dienemann, Hendrik
AU - Muley, Thomas
N1 - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
PY - 2011/12
Y1 - 2011/12
N2 - Objectives: To study the prognostic impact of the different forms of the receptor for urokinase plasminogen activator (uPAR) in serum from 171 non-small cell lung cancer (NSCLC) patients. Materials and methods: Serum sampled preoperatively was available from 171 patients radically resected for NSCLC. Intact uPAR, uPAR(I-III), intact and cleaved uPAR, uPAR(I-III) + uPAR(II-III) and the liberated uPAR(I) were measured by time-resolved fluorescence immunoassays (TR-FIAs 1-3). Results: High serum levels of each of the three uPAR forms were associated with short overall survival (OS). In a multivariate survival analysis uPAR(I-III) (hazard ratio (HR)=2.3, 95% confidence interval (CI): 1.2-4.5, p=0.015) and uPAR(I) (hazard ratio (HR) =1.5, 95% CI: 1.0-2.2, p=0.0497) remained significant prognostic parameters independent of stage, histology, age, performance status and therapy. Conclusions: This retrospective study shows that uPAR(I-III) and uPAR(I) in serum are independent prognostic factors in patients radically operated for NSCLC. Further prospective studies are needed to validate these markers for clinical use.
AB - Objectives: To study the prognostic impact of the different forms of the receptor for urokinase plasminogen activator (uPAR) in serum from 171 non-small cell lung cancer (NSCLC) patients. Materials and methods: Serum sampled preoperatively was available from 171 patients radically resected for NSCLC. Intact uPAR, uPAR(I-III), intact and cleaved uPAR, uPAR(I-III) + uPAR(II-III) and the liberated uPAR(I) were measured by time-resolved fluorescence immunoassays (TR-FIAs 1-3). Results: High serum levels of each of the three uPAR forms were associated with short overall survival (OS). In a multivariate survival analysis uPAR(I-III) (hazard ratio (HR)=2.3, 95% confidence interval (CI): 1.2-4.5, p=0.015) and uPAR(I) (hazard ratio (HR) =1.5, 95% CI: 1.0-2.2, p=0.0497) remained significant prognostic parameters independent of stage, histology, age, performance status and therapy. Conclusions: This retrospective study shows that uPAR(I-III) and uPAR(I) in serum are independent prognostic factors in patients radically operated for NSCLC. Further prospective studies are needed to validate these markers for clinical use.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Carcinoma, Non-Small-Cell Lung
KW - Female
KW - Humans
KW - Immunoassay
KW - Male
KW - Middle Aged
KW - Plasminogen Activators
KW - Prognosis
KW - Urokinase-Type Plasminogen Activator
U2 - 10.1016/j.lungcan.2011.05.008
DO - 10.1016/j.lungcan.2011.05.008
M3 - Journal article
C2 - 21640427
SN - 0169-5002
VL - 74
SP - 510
EP - 515
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -
